GlassScriptPhysician profile
Karen E Neubauer
NPI 1255377958
$5,577.42
in general payments reported to CMS, 2019-2025
29 companies · $779 in 2025
The $779 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $228 · 2021: $217 · 2022: $598 · 2023: $1,585 · 2024: $1,284 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,647.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,000.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $886.00 | 2019-2025 | |
| Lilly USA, LLC | $345.79 | 2019-2025 | Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $323.15 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $274.76 | 2019-2023 | Ilumya, Winlevi |
| Pfizer INC. | $240.76 | 2022-2025 | |
| Incyte Corporation | $232.48 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $231.09 | 2022-2025 | Adbry, Spevigo |
| Regeneron Healthcare Solutions, INC. | $224.91 | 2019-2025 | Dupixent |
| Amgen INC. | $217.54 | 2022-2024 | Otezla |
| Genzyme Corporation | $180.11 | 2019-2025 | |
| Galderma Laboratories, L.P. | $160.98 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $155.29 | 2024 | Zoryve |
| Celgene Corporation | $127.20 | 2019 | |
| Janssen Biotech, INC. | $120.99 | 2021-2023 | Tremfya |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $109.55 | 2019-2022 | |
| Organogenesis INC. | $107.36 | 2023-2024 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.07 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $87.14 | 2023-2024 | Vtama |
| Almirall LLC | $84.28 | 2020-2025 | Klisyri |
| Genentech USA, INC. | $73.30 | 2019-2023 | Erivedge |
| Convatec INC. | $67.14 | 2024 | |
| Ucb, INC. | $57.46 | 2024-2025 | Bimzelx |
| Fresenius Kabi USA, LLC | $43.49 | 2023 | |
| Dusa Pharmaceuticals, INC. | $41.17 | 2019 | |
| Kerecis Limited | $36.79 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Hydrofera LLC | $22.06 | 2025 | Hydrofera Blue |
| Kyowa Kirin, INC. | $18.91 | 2023 | Poteligeo |
| Mallinckrodt Hospital Products INC. | $18.48 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Neubauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.